Labcorp Receives FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx

PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C. , Aug. 2, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory

Comprehensive laboratory testing for gene therapies

Comprehensive laboratory testing for adoptive cell therapies: Supporting preclinical and clinical testing to advance your precision medicine initiative

Beyond Alzheimer’s: How Labcorp’s leadership in Alzheimer’s disease testing is guiding work in other neurological diseases

Nearly 7 million people in the U.S. live with Alzheimer’s disease, and that number is expected to grow to 12.7 million by 2050 if there are no major breakthroughs to improve diagnoses, monitoring and treatment.

Labcorp Announces 2024 Second Quarter Results

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance:

A deeper dive into the tumor-infiltrating T Cell immunophenotype

In this Tech Spotlight, we demonstrate the latter capability by presenting data generated using the new Expanded CompT™ panel, a 16-color panel that takes flow analysis of T cell activation and differentiation to a level above any other panel in the Labcorp service portfolio.

Explore tissue heterogeneity through spatial transcriptomic profiling

Author: Dan Saims, In Vitro Scientist II and Gunisha Arora, Medical and Scientific WriterDate: March 2024

Clinical Performance of a Plasma ATN Panel for Assessment of Alzheimer’s Disease

Authors: B. B. Collier, W. C. Brandon, M. R. Chappell, A. B. Harris, T. Le, R. L. Martone, J. M. Volpe, D. Boles, A. Valcour, R. P. Grant

Good laboratory stewardship: Transitioning from clinician-ordered peripheral smear reviews to laboratory-derived smear reviews (via a complete blood count with differential)

In conjunction with good laboratory stewardship, best practices and clinical evidence, Labcorp has discontinued the clinician-ordered Hematopathology Consultation, Peripheral Smear (test number 005300) in favor of a Complete Blood Count (CBC) with Differential (test number 005009).

How to interpret unexpected results due to patient metabolism or adulterated urine